PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.

CONCLUSIONS: These results identify FGF14 as a potential PPARγ-sensitive target controlling Aβ-induced dysfunctions of neuronal activity in the DG underlying memory loss in early AD. PMID: 28522250 [PubMed - as supplied by publisher]
Source: Experimental Neurology - Category: Neurology Authors: Tags: Exp Neurol Source Type: research

Related Links:

Authors: Rao YL, Ganaraja B, Joy T, Pai MM, Ullal SD, Murlimanju BV Abstract Alzheimer's disease (AD) is a neurodegenerative disorder, which is commonly seen in older individuals. This is characterized by cognitive dysfunction, which leads to dementia. Pharmacological treatments for AD are mainly targeted on its symptoms like memory loss and cognitive impairment. The pathophysiology involved in AD is intra-neuronal accumulation of hyper-phosphorylated tau protein as neurofibrillary tangle and extra cellular beta amyloid plaque deposition, which is due to oxidative stress. Here we review the neuro-protective effects...
Source: Frontiers in Bioscience - Elite - Category: Biomedical Science Tags: Front Biosci (Elite Ed) Source Type: research
To delay or prevent the onset of memory loss, talk to your doctor. It can really be that simple. Among the diseases that Americans fear most, Alzheimer ’s and dementia consistently rank at the top of the list. What people don’t always realize is that many causes of memory loss are treatable and preventable, and the […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Neurology Primary Care Source Type: blogs
After spending 30 minutes hunting for your car in a parking lot, or getting lost on a familiar route, have you ever considered asking your doctor for a blood test or brain scan to find out if you have Alzheimer’s disease? A number of factors contribute to Alzheimer’s disease. By definition, this form of dementia involves the buildup of a protein in brain called beta-amyloid. Beta-amyloid forms plaques that disrupt communication between brain cells, and ultimately destroys them. For this reason, tests for Alzheimer’s disease focus on beta-amyloid. Blood tests for Alzheimer’s disease are being develop...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Alzheimer's Disease Healthy Aging Memory Tests and procedures Source Type: blogs
(Natural News) Poria mushrooms (Poria cocos), also known as fuling in traditional Chinese medicine (TCM), has long been used as a diuretic, tonic, and sedative in both Chinese and Japanese medicines. Today, it is known to treat a wide variety of diseases, ranging from coughs and diarrhea to loss of memory (amnesia) and Alzheimer’s disease....
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
A clinical trial has found that an innovative electromagnetic therapy device significantly reduced memory loss in seven out of the eight participants.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
“Get out! Get out!” My wife, Joan, having just woken up, was screaming, and hitting out wildly at the stranger in her bed. She was in a panic, her body shaking with fright. “Get away from here. Get out!” The man she perceived as a stranger was me, her husband of more than forty years. Joan was eight years into the destructive course of atypical early-onset Alzheimer’s disease, a horrific disorder that ravaged her, leaving her blind and with serious dementia. At that moment, she was experiencing something called Capgras Syndrome, in which patients become deluded that those close to them and the...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Books health ideas Source Type: news
Researchers at private Arizona-based firm NeuroEM Therapeutics tested their transcranial electromagnetic treatment (TEMT) on a group of eight patients with mild or moderate Alzheimer's.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
, de Oliveira ACP Abstract Alzheimer's Disease (AD) is the most prevalent neurodegenerative disorder. Despite advances in the understanding of its pathophysiology, none of the available therapies prevents disease progression. Excess glutamate plays an important role in excitotoxicity by activating ionotropic receptors. However, the mechanisms modulating neuronal cell survival/death via metabotropic glutamate receptors (mGluRs) are not completely understood. Recent data indicates that CDPPB, a positive allosteric modulator of mGluR5, has neuroprotective effects. Thus, this work aimed to investigate CDPPB treatment ...
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Neuropharmacology Source Type: research
Publication date: Available online 12 September 2019Source: Molecular and Cellular NeuroscienceAuthor(s): Melissa L. Young, James L. FranklinAbstractOxidative stress, likely stemming from dysfunctional mitochondria, occurs before major cognitive deficits and neuropathologies become apparent in Alzheimer's disease (AD) patients and in mouse models of the disease. We previously reported that treating 2- to 7-month-old 3xTg-AD mice with the mitochondria-targeted antioxidant MitoQ (mitoquinone mesylate: [10-(4,5-Dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl](triphenyl)phosphonium methanesulfonate), a period when AD...
Source: Molecular and Cellular Neuroscience - Category: Neuroscience Source Type: research
Alzheimer's disease (AD) is the most common cause of dementia but the changes in brain cell function underlying memory loss remains poorly understood. Researchers at the University of Bristol have identified that calcium channel blockers may be effective in treating memory loss.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Life Sciences, Faculty of Life Sciences, School of Physiology, Pharmacology and Neuroscience; Press Release Source Type: news
More News: Alzheimer's | Amnesia | Avandia | Biochemistry | Brain | Insulin | Nanotechnology | Neurology | Pathology